Trials / Completed
CompletedNCT00108914
Perennial Allergic Rhinitis Study In Pediatric Subjects
A Two Week Randomized, Double Blind Placebo Controlled, Parallel Group Study of GW685698X Aqueous Nasal Spray 100mcg and 50mcg QD in Pediatric Subjects With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 558 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 2 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.
Detailed description
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 12 Weeks in Pediatric Subjects Ages 2 to \<12 Years with Perennial Allergic Rhinitis (PAR)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW685698X |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-04-21
- Last updated
- 2017-01-19
Locations
66 sites across 7 countries: United States, Argentina, Chile, Finland, Italy, Mexico, Slovakia
Source: ClinicalTrials.gov record NCT00108914. Inclusion in this directory is not an endorsement.